Integra LifeSciences stock reaches 100-patient AERA milestone
Published on 09/30/2026 at 22:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Integra LifeSciences stock gets a clinical milestone after the company reported that its AERA Pediatric Registry had enrolled 100 patients by September 29, 2026. The total represents one-third of the planned 300-patient registry and expands the evidence base for a pediatric Eustachian tube treatment.
AERA reaches one-third of plan
According to GlobeNewswire on September 29, 2026, the prospective multicenter registry is evaluating the Acclarent AERA Eustachian Tube Balloon Dilation System in patients ages eight and older. The registry launched in July 2025 and is designed to collect real-world evidence from U.S. clinical sites.
AERA received FDA clearance for its pediatric indication in December 2023, according to the company release carried by GlobeNewswire. The current enrollment milestone is operational rather than financial, but it gives investors a measurable checkpoint for the company's ENT strategy.
Q2 earnings beat consensus
Integra reported second-quarter 2026 revenue of USD 418.76 million and adjusted EPS of USD 0.56, versus consensus EPS of USD 0.48, according to Zacks. The adjusted EPS result was USD 0.08 above consensus, creating a concrete comparison for the clinical milestone story.
The same Zacks report said management kept full-year 2026 adjusted EPS guidance at USD 2.40-2.50. Adjusted gross margin reached 61.3 percent in the second quarter, while adjusted EBITDA margin was 18.7 percent, showing where operating execution matters beyond product enrollment.
Nasdaq quote sets market context
Integra LifeSciences was last quoted at USD 16.28 on Nasdaq on September 30, 2026 at 4:00 p.m. ET. The quote was USD 0.36 below the prior close of USD 16.64, or minus 2.16 percent, while the 52-week range stood at USD 8.70 to USD 20.49 and market capitalization at USD 1.3 billion.
Integra LifeSciences stock facts
- Company: Integra LifeSciences Holdings Corporation
- Ticker: IART
- Primary exchange: Nasdaq Global Select Market
- Market price: USD 16.28 on Nasdaq as of September 30, 2026 at 4:00 p.m. ET
- Market capitalization: USD 1.3 billion as of September 30, 2026
- 52-week range: USD 8.70-20.49
- Sector / Industry: Healthcare / Medical Devices
- Next earnings date: October 29, 2026
